Abstract
Gene therapy for advanced breast cancer is anticipated to be a useful therapeutic approach. Strategies in ongoing clinical protocols can be divided into four groups: (1) suppression of oncogenes or transfer of tumor-suppressor genes: (2) enhancement of immunological response: (3) transfer of suicide genes: (4) protection of bone marrow using drug resistance genes. We have started a clinical study of multidrug resistance (MDR1) gene therapy. Patients received high dose chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT) with MDR1-transduced hematopoietic cells, and then were treated with docetaxel. Three patients have been treated so far, and in vivo enrichment of MDR1-transduced cells with docetaxel treatment has been seen. There has been no apparent adverse effect from the MDR1 gene transfer.
| Original language | English |
|---|---|
| Pages (from-to) | 563-569 |
| Number of pages | 7 |
| Journal | Nippon rinsho. Japanese journal of clinical medicine |
| Volume | 64 |
| Issue number | 3 |
| Publication status | Published - 2006 Mar |
| Externally published | Yes |
ASJC Scopus subject areas
- Medicine(all)
